Blood neurofilament light levels predict non-relapsing progression following anti-CD20 therapy in relapsing and primary progressive multiple sclerosis: findings from the ocrelizumab randomised, double-blind phase 3 clinical trials
Amit Bar-Or, Gian Andrea Thanei, Christopher Harp, Corrado Bernasconi, Ulrike Bonati, Anne H. Cross, Saloumeh Fischer, Laura Gaetano, Stephen L. Hauser, Robert Hendricks, Ludwig Kappos, Jens Kuhle, David Leppert, Fabian Model, Annette Sauter, Harold Koendgen, Xiaoming Jia, Ann E. Herman
Dive into the research topics of 'Blood neurofilament light levels predict non-relapsing progression following anti-CD20 therapy in relapsing and primary progressive multiple sclerosis: findings from the ocrelizumab randomised, double-blind phase 3 clinical trials'. Together they form a unique fingerprint.